Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Downregulated PIRH2 Can Decrease the Proliferation of Breast Cancer Cells

(2016) Shuyun Yang et al.   ARCHIVES OF MEDICAL RESEARCH

TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition

(2016) Prahlad V. Raninga et al.   CELL CYCLE

E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers

(2016) Kazuma Masumoto et al.   CURRENT CANCER DRUG TARGETS

Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma

(2016) E Malek et al.   LEUKEMIA

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase

(2016) Georg Petzold et al.   NATURE

Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors

(2016) Angel Chao et al.   Taiwanese Journal of Obstetrics & Gynecology

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

(2016) Joel G. Turner et al.   Oncotarget

Myeloma today: Disease definitions and treatment advances

(2015) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Heat shock protein gp96 decreases p53 stability by regulating Mdm2 E3 ligase activity in liver cancer

(2015) Bo Wu et al.   CANCER LETTERS

Molecular basis of resistance to proteasome inhibitors in hematological malignancies

(2015) Denise Niewerth et al.   DRUG RESISTANCE UPDATES

E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy

(2015) Zhonglin Hao   Frontiers in Bioscience-Landmark

Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake

(2015) Jessica Kristine Nelson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma

(2015) Kristina Bielskienė et al.   Medicina-Lithuania

Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression

(2015) E T Goka et al.   ONCOGENE

Role of E3 ubiquitin ligases in gastric cancer

(2015) Ya-Chao Hou et al.   WORLD JOURNAL OF GASTROENTEROLOGY

E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma

(2015) Kristina Bielskienė et al.   Medicina-Lithuania

Regulation of the DNA damage response by ubiquitin conjugation

(2015) Kerstin Brinkmann et al.   Frontiers in Genetics

Hypoxic Regulation of Glutamine Metabolism through HIF1 and SIAH2 Supports Lipid Synthesis that Is Necessary for Tumor Growth

(2014) Ramon C. Sun et al.   Cell Metabolism

The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma

(2014) Jie Yin et al.   INTERNATIONAL JOURNAL OF CANCER

E3 ubiquitin ligases and human papillomavirus-induced carcinogenesis

(2014) Zhifeng Lou et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases

(2014) P. Sharma et al.   Open Biology

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pirh2

(2013) Marie-jo Halaby et al.   CELL CYCLE

Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies

(2013) Lindsey N. Micel et al.   JOURNAL OF CLINICAL ONCOLOGY

The Significance of Ubiquitin Proteasome Pathway in Cancer Development

(2013) Azmi Yerlikaya et al.   Recent Patents on Anti-Cancer Drug Discovery

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis

(2013) N Sévère et al.   Cell Death & Disease

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

Pirh2 RING-finger E3 ubiquitin ligase: Its role in tumorigenesis and cancer therapy

(2012) Yong-Sam Jung et al.   FEBS LETTERS

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

(2012) R. J. Jones et al.   MOLECULAR CANCER THERAPEUTICS

Role of Pirh2 in Mediating the Regulation of p53 and c-Myc

(2011) Anne Hakem et al.   PLoS Genetics

Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis

(2011) Guocan Wang et al.   Chinese Journal of Cancer

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

(2009) M. G. Ooi et al.   CLINICAL CANCER RESEARCH

Many facets of bortezomib resistance/susceptibility

(2008) S. Kumar et al.   BLOOD